No Data
Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte)
Global LAG-3 Inhibitors Market, Drug Sales & Clinical Trials Market Report: Featuring Abeome, ABL Bio, Agenus, Akeso Biopharma, AnaptysBio, EpimAb Biotherapeutics, Immutep, Incyte and Y-Biologics
Analyst Expectations For Incyte's Future
6 analysts have shared their evaluations of Incyte (NASDAQ:INCY) during the recent three months, expressing a mix of bullish and bearish perspectives.The table below provides a snapshot of their recen
Cantor Fitzgerald Reiterates Neutral on Incyte
Cantor Fitzgerald analyst Eric Schmidt reiterates Incyte (NASDAQ:INCY) with a Neutral.
Incyte Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/18/2024 — Cantor Fitzgerald Reiterates → Neutral 05/23/2024 -12.27% Deutsche Bank → $55 Initiates Cove
Research Alert: CFRA Keeps Buy View On Shares Of Incyte Corporation
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: Following the solid rally seen Incyte Co